Lilly Targets Watson Over Osteoporosis Drug ANDA

Law360, New York (May 5, 2010, 12:53 PM EDT) -- Eli Lilly & Co. has filed a patent infringement suit against Watson Pharmaceuticals Inc. over the rival drugmaker's plans to market a generic version of postmenopausal osteoporosis treatment Evista.

The complaint, filed Monday in the U.S. District Court for the Southern District of Indiana, argues that Watson’s abbreviated new drug application to market generic Evista will lead to direct infringement of three patents.

Each of the asserted patents — U.S. Patent Numbers 6,458,811; 6,797,719; and 6,894,064 — cover the formulation for raloxifene hydrochloride, or Evista, the...
To view the full article, register now.